Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. - sprookjes - yvandenbroek - TriplyDB

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q37008223

about

Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.Immune-based therapeutics for pediatric cancer.Immunotherapy of childhood cancer: from biologic understanding to clinical application.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.Cancer immunotherapy comes of age A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.The role of second transplants for leukemia.Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions.Cellular therapies in acute lymphoblastic leukemia Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation.Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.Recent advances in quantitative chimerism analysis.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Relapse after allogeneic stem cell transplantation Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.Immunotherapy in acute myeloid leukemia.Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells.Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15.Cellular therapies in acute lymphoblastic leukemia.NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.αβ-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.

P2860

Q28079823-DC3475AE-0218-4AE0-99EA-23A45119CB25 Q28084879-9F9C7E3C-E25B-486F-8895-AC84B86920CA Q33482103-EA85078D-7905-4E7B-9EAC-876C63A4BD16 Q33604121-6F53561C-C62A-4271-B2EF-9D4AA3F0D54A Q33752982-FCCD4C02-E20E-42F9-9CA8-5188EA6B3C80 Q34202277-5A2B8AD9-AA5F-4ABA-BB6D-CC03BBA3E623 Q35085209-D4BD43DE-97A4-4761-A99F-9874A9BEF33F Q35666338-5AA5805D-B448-4906-8141-C6EC985E1B29 Q36062047-9DFE7669-AF3C-46D7-A5E7-3ABFFC263561 Q36204850-0FFD6D89-54D8-4AA4-85F9-89084750CF77 Q36375715-DEECA164-61B2-49ED-A975-2596C20A81EB Q36552098-6F188075-50C3-4B6C-8BE7-BC1708CD02EA Q36623397-BAC3C022-CA74-4AF7-A75A-94ACFA49FB10 Q36961764-56F96903-0FEB-4B32-A67F-EF457449CDED Q37416883-8F1B3F67-4DDE-4E59-B66F-C80FA88AA24B Q37628681-CC3896BC-EDB5-48DC-936C-60920AD4E27B Q37810098-287920AC-3599-464B-8CBD-25B53142212B Q37810125-FC0B173C-5E3B-4413-8CEE-B4E6A458FB42 Q37905034-77EA28C4-E81D-4B5F-A70A-B5054A6D969E Q38103578-72BDB440-7EC6-468A-833A-94B039FC6C7E Q38171574-783C1690-37A3-433B-92CE-DBBBBF759CD8 Q38177364-0B56211B-DB96-4B08-A504-EEC4820D12D0 Q38197075-B51AD799-5376-4049-93B7-98C3F65AE553 Q38887291-AF13854C-9869-4B17-9750-68209D475AFF Q39106490-84541640-C5FE-4B6D-B221-52DF5E8F12C3 Q39682472-40F715E7-AC60-4925-9C64-015BD1ABE3CB Q40966061-80FBE712-0744-4B8F-BF30-8313B3B0E8BB Q41387613-3D3FFEB1-8E26-45CD-8A93-5570EA62E819 Q41560177-1F553702-17B9-4E65-AC37-A43E280A06AC Q43610177-8625FF2F-0BC0-44F0-A733-6B264C4D7229 Q44208467-E7DFF429-2125-4FA6-B105-F0F467DBB279 Q44919804-517A10B0-7E0B-43F8-B8B1-225200806D1E Q47241481-FCDF3715-3E24-4147-B9BF-6401C808F39F Q47564596-83B8011D-37E7-4870-B0B4-AED644DE9832 Q47855599-B8C98EF0-A0E7-4E59-A046-70F5F33B5EBB Q50225357-769289BC-F033-4933-B3FC-53055F8D2C6F

P2860

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q37008223

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Donor leukocyte infusions for ...... eic stem cell transplantation.

@en

Donor leukocyte infusions for ...... eic stem cell transplantation.

@nl

type

label

Donor leukocyte infusions for ...... eic stem cell transplantation.

@en

Donor leukocyte infusions for ...... eic stem cell transplantation.

@nl

prefLabel

Donor leukocyte infusions for ...... eic stem cell transplantation.

@en

Donor leukocyte infusions for ...... eic stem cell transplantation.

@nl

P1433

Q37008223-62C2FB0B-069F-4D26-9D75-7FAD4B26F332

P1476

Q37008223-358DBC78-3FE1-4DED-8E3B-16D6C1BBA038

P2093

Q37008223-52861E2F-E812-479E-9E0B-0D8053592AA8

Q37008223-C5A1E736-7415-482B-AB8B-452D31398C50

P2860

Q37008223-00592F9F-5D1A-49A2-BBF9-9A802AC5AAE1

Q37008223-051894E1-3F22-4CDD-AD53-1306C9F7B91B

Q37008223-1F0680ED-F1A3-4161-ACD1-E7C65A2DAE85

Q37008223-2C628710-44AB-46D1-BE65-59AA7C4D716D

Q37008223-3103D3DB-9DBC-42C1-ADA4-DC109F01BA12

Q37008223-326CDBDF-0304-4ADD-82B6-99CDE630A0F6

Q37008223-444B319B-4FC1-41D3-9A48-B75A5A6E2F10

Q37008223-4A6C4530-012E-48AB-993C-5DB351BA2C5C

Q37008223-51FA4149-1489-45D7-8292-5754DB1BE34D

Q37008223-5430D849-3E92-4053-B27D-B723C2BAD0EB

P2888

Q37008223-15B8D260-5940-4CDF-A334-6DBA57059020

P304

Q37008223-C59CB9EF-B9B3-4F5D-B97A-C4736A826B0E

P31

Q37008223-C35E33F9-9113-4A14-9998-F4B2C8558B87

P356

Q37008223-9B8EC122-1796-4BE7-A410-48C06D490E4C

P407

Q37008223-402A0994-A4E0-4E3B-99BE-A34C2794B2A0

P433

Q37008223-7117547B-E05D-461E-85AF-8308F653A23B

P478

Q37008223-5DED441A-D0E9-46E1-A508-BD1EC88238D5

P577

Q37008223-B7437F30-60A2-4036-8080-FFA131E7171A

P5875

Q37008223-82AB97F8-C44D-4ACE-90EC-07FA7FACC649

P698

Q37008223-74404EA8-86FB-44AE-8148-E27441928003

P921

Q37008223-F130F057-24E9-4421-94AD-EBC2FEDC4579

P356

P1433

Bone Marrow Transplantation

P1476

Donor leukocyte infusions for ...... eic stem cell transplantation.

@en

P2093

Loren AW

http://www.w3.org/2001/XMLSchema#string

Porter DL

http://www.w3.org/2001/XMLSchema#string

P2860

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.

Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.

Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy.

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Bl

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.

Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.

Optimizing engraftment--source and dose of stem cells.

P2888

P304

483-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705898

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5821394

http://www.w3.org/2001/XMLSchema#string

P698

18026156

http://www.w3.org/2001/XMLSchema#string

P921